City of Hope hematologist/oncologist Joseph Alvarnas shares his perspectives on how CAR-T therapies are requiring new models of health care delivery and engagement with more kinds of stakeholders, during an interview at the recent ASH annual meeting.

The majority of pharmaceutical companies in the UK work closely with the NHS and In Vivo spoke to one of them – Janssen – to see how successful industry, health care providers and payers have been in breaking out of their silos and collaborating.

Pharmaceutical companies cannot afford to ignore the growing number of cross-country collaborations springing up in Europe aimed at securing more affordable medicines through actions such as jointly negotiated pricing deals. In Vivo looks at the factors that may influence the rise or fall of these collaborations and at how they may eventually make companies rethink the way they do business.

2018 is set to break the record for new drug approvals in China, which have included some immuno-oncology and powerful antiviral therapies. Providing access to these high-priced medicines to more patients in the populous country was high on the minds of several multinationals during a recent conference in Shanghai.

One day after CVS' $70bn acquisition of Aetna closed, CEO Larry Merlo spoke at the Forbes Healthcare Summit about why the vertical integration makes sense and how it will contribute to lower healthcare spending.

India’s new government-funded health care program expects to expand access to treatment to more than 100 million families. Can it effectively deliver on its promise and also materially expand opportunities for hospitals and pharma?

The European Commission has officially approved Luxturna, Novartis/Spark Therapeutics’ transformative gene therapy. The Swiss firm tells Scrip how the lessons it expects to learn from launching its first gene therapy will inform its future strategy in this new field.

After an advisory committee recommended approval for the postpartum depression treatment if administered under a REMS program at certified centers, Sage submitted a proposed REMS, causing the agency to extend the PDUFA date three months.

Already outdated? The latest ACC/AHA guidelines say at mid-2018 list prices, PCSK9 injectables are of low value, but the costs have plummeted since then.